Novyra Pharmachem Proposes Capital Reduction Scheme

Novyra Pharmachem Limited will reduce its paid-up equity share capital by 85.71%, cancelling 54.25 lakh shares.

Reader Takeaway: Balance sheet cleanup aims for future fundraising; operational turnaround remains key.

What just happened

Novyra Pharmachem Limited has announced a Scheme of Capital Reduction. This plan aims to eliminate accumulated losses by cancelling 54.25 lakh equity shares. The company's paid-up equity share capital will reduce from ₹6.33 crore to ₹0.90 crore.

Why this matters

The capital reduction is a crucial step for Novyra Pharmachem to clean up its balance sheet. By writing off ₹5.43 crore in accumulated losses, the company aims to present a more accurate financial picture. This move is intended to facilitate future fundraising efforts, which are essential for its strategic pivot.

The backstory

Novyra Pharmachem has a history of accumulated losses dating back to FY 2014-15. The company has undergone a significant strategic shift, moving away from its tea industry roots to focus on pharmaceuticals, real estate, and tea estate segments. Its registered office has also been relocated from West Bengal to Gujarat.

What changes now

Following the capital reduction, the company's paid-up capital will be substantially lower. The cancellation of shares means a significant dilution for existing shareholders not participating in future fundraising. The company expects this restructuring to pave the way for new capital infusion.

Risks to watch

The primary risk is the execution of the new business strategy in the pharmaceutical and real estate sectors. The company must demonstrate its ability to generate sustainable profits to justify the capital reduction and attract new investors. The pivot itself carries inherent risks.

Peer comparison

Information regarding comparable companies undertaking similar capital reduction schemes in the pharmaceutical or diversified sectors is not provided in the filing. The capital reduction is a specific balance sheet exercise rather than an operational or market-based comparison.

Context metrics

For FY 2025-26, Novyra Pharmachem reported revenue from operations of ₹0.1044 crore (₹10.44 lakh) and a net loss of ₹5.37 crore (₹537.38 lakh). As of March 31, 2026, accumulated losses stood at ₹5.71 crore (₹570.79 lakh).

What to track next

Investors should monitor Novyra Pharmachem's progress in its new business segments and its success in raising fresh capital. The company's ability to achieve profitability and improve its financial health will be key indicators.